

ASX Announcement

Medibio Limited – 17 February 2022



Medibio strengthens Board of Directors with the appointment of Stephen Mitchley as Non-Executive Director

Melbourne, Australia and Minneapolis, MN – 17 February 2022: Medibio Limited (“MEB” or “Medibio”) (ASX: MEB) (OTCPINK: MDBIF) is pleased to welcome Stephen Mitchley on Medibio’s Board of Directors as Non-Executive Director with immediate effect.

Stephen is based in New York and leads Vitality Group’s digital and global partner disciplines. He brings 25 years of experience and expertise in overseeing operations and technology to the Vitality Group product team. Mitchley joined South Africa-based Discovery Holdings Limited, the parent company of Vitality Group, in 2000 and has led large-scale process re-engineering activities and designed and built operations for new products and services. In 2008 he moved to the US to help found the Vitality Group as COO. A global health and wellness company, Vitality Group blends industry-leading smart tech, data, incentives and behavioral science to inspire healthy changes in individuals and organizations.

“The pandemic has increased the need for mental health services with almost half of large employers noting an increase in use of these services by employees, said Mitchley. “Medibio’s pioneering work in identifying biometric data for mental health conditions could not be more opportune. The combination of processing smart watch signals and their consumer and corporate apps has such potential to destigmatize mental conditions and provide evidence-based support. I share the company’s vision and look forward to making a strong contribution to the mission of empowering mental wellness.”

“I am delighted to have Stephen Mitchley join Medibio’s Board of Directors,” said Medibio Co-Founder and Managing Director Claude Solitario. “His knowledge and experience in the health and wellness industry via the Vitality Group is exemplary. I look forward to his contribution to the Board, in particular his counsel and guidance regarding our go-to-market strategy in the US.”

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

For Further information:

Claude Solitario
Managing Director & CEO
T: +61 3 9692 7222

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Level 4, 100 Albert Road, South Melbourne, Vic 3205
Email: info@medibio.com.au | www.medibio.com.au
ACN: 008 130 336